Enhancement of radiation response of prostatic carcinoma by lonidamine

S. D. Dudak, A. Lopez, Norman L Block, B. L. Lokeshwar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Potential application of lonidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50% inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2 depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model consistent with its in vitro effect on the same cell fine. LND did not alter the primary growth of the tumor. Fractionated irradiation caused a 40% decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.

Original languageEnglish
Pages (from-to)3665-3671
Number of pages7
JournalAnticancer Research
Volume16
Issue number6 B
StatePublished - Dec 1 1996

Fingerprint

Radiation
Carcinoma
Neoplasms
Prostatic Neoplasms
Growth
Dose Fractionation
Cell Line
Inhibitory Concentration 50
lonidamine
Neoplasm Metastasis
Lung
Injections
Therapeutics

Keywords

  • Adjuvant therapy
  • Lonidamine
  • Prostate cancer
  • Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dudak, S. D., Lopez, A., Block, N. L., & Lokeshwar, B. L. (1996). Enhancement of radiation response of prostatic carcinoma by lonidamine. Anticancer Research, 16(6 B), 3665-3671.

Enhancement of radiation response of prostatic carcinoma by lonidamine. / Dudak, S. D.; Lopez, A.; Block, Norman L; Lokeshwar, B. L.

In: Anticancer Research, Vol. 16, No. 6 B, 01.12.1996, p. 3665-3671.

Research output: Contribution to journalArticle

Dudak, SD, Lopez, A, Block, NL & Lokeshwar, BL 1996, 'Enhancement of radiation response of prostatic carcinoma by lonidamine', Anticancer Research, vol. 16, no. 6 B, pp. 3665-3671.
Dudak SD, Lopez A, Block NL, Lokeshwar BL. Enhancement of radiation response of prostatic carcinoma by lonidamine. Anticancer Research. 1996 Dec 1;16(6 B):3665-3671.
Dudak, S. D. ; Lopez, A. ; Block, Norman L ; Lokeshwar, B. L. / Enhancement of radiation response of prostatic carcinoma by lonidamine. In: Anticancer Research. 1996 ; Vol. 16, No. 6 B. pp. 3665-3671.
@article{d4078fd19ca1451fb92585e183159eb5,
title = "Enhancement of radiation response of prostatic carcinoma by lonidamine",
abstract = "Potential application of lonidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50{\%} inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2 depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model consistent with its in vitro effect on the same cell fine. LND did not alter the primary growth of the tumor. Fractionated irradiation caused a 40{\%} decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.",
keywords = "Adjuvant therapy, Lonidamine, Prostate cancer, Radiation",
author = "Dudak, {S. D.} and A. Lopez and Block, {Norman L} and Lokeshwar, {B. L.}",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "16",
pages = "3665--3671",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Enhancement of radiation response of prostatic carcinoma by lonidamine

AU - Dudak, S. D.

AU - Lopez, A.

AU - Block, Norman L

AU - Lokeshwar, B. L.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Potential application of lonidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50% inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2 depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model consistent with its in vitro effect on the same cell fine. LND did not alter the primary growth of the tumor. Fractionated irradiation caused a 40% decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.

AB - Potential application of lonidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50% inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2 depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model consistent with its in vitro effect on the same cell fine. LND did not alter the primary growth of the tumor. Fractionated irradiation caused a 40% decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.

KW - Adjuvant therapy

KW - Lonidamine

KW - Prostate cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0030514287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030514287&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 3665

EP - 3671

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -